Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the ...

Adaptive Biotechnologies Corporation ADPT shares are trading higher during Tuesday’s session as the company has announced ...

MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differentiated ...

Adaptive Biotechnologies attracts attention as immune medicine innovation, diagnostic advancements, and biotechnology ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the best growth stocks under $20 to buy. On May 5, Adaptive Biotechnologies reported strong Q1 2026 results, with total revenue reaching ...

Adaptive Biotechnologies (ADPT) has priced its private offering of senior unsecured convertible notes due 2031. Due to strong institutional demand, the aggregate principal amount of the offering was ...

Julie Rubinstein, the president and COO of Adaptive Biotechnologies (NASDAQ:ADPT), reported the sale of 179,703 shares of Common Stock between March 11, 2026 and March 13, 2026, following an option ...

Transaction value based on SEC Form 4 weighted average purchase price ($14.45); post-transaction value based on April 16, 2026, market close ($14.08). Offers immunosequencing and diagnostic platforms, ...

Adaptive Biotechnologies said on Monday it planned to separate its immune medicine ​business from its residual cancer-testing unit, ‌as it reviews options for the drug-discovery business and focuses ...

In the last three months, 4 analysts have published ratings on Adaptive Biotechnologies (NASDAQ:ADPT), offering a diverse range of perspectives from bullish to bearish. The table below provides a ...

Chief People Officer Francis Lo disposed of 39,741 Common Stock shares on June 4, 2026, for a total transaction value of ~$695,000 based on a weighted average price of $17.49 per share. The ...